GLP-3R
Represents the investigational active ingredient retatrutide — a triple GIP/GLP-1/glucagon receptor agonist
A metabolic health therapy built on retatrutide, an investigational triple-receptor compound currently being studied in human clinical trials.
What Is GLP-3R?
Why Is GLP-3R Being Studied?
- Triple incretin and glucagon receptor activation
- Body weight and fat mass reduction
- Insulin sensitivity
- Energy expenditure signaling
How Does It Work?
Retatrutide is designed to activate the GIP receptor, GLP-1 receptor, and glucagon receptor simultaneously. Researchers have proposed that adding glucagon receptor activity to the GIP/GLP-1 mechanism may further influence energy expenditure and fat metabolism, in addition to the appetite and blood-sugar effects associated with GIP/GLP-1 activation alone.
Retatrutide (investigational active ingredient)
GIP, GLP-1 & glucagon receptor activation
Appetite, insulin & energy expenditure pathways
Metabolic outcomes under active clinical investigation
What Does The Evidence Say?
Human Research
Retatrutide has been studied in published Phase 2 randomized clinical trials examining body weight and metabolic markers in human participants. As of this writing, it has not completed Phase 3 trials or received FDA approval.
Preclinical Research
Preclinical pharmacology studies characterized retatrutide's receptor activity across GIP, GLP-1, and glucagon pathways prior to human trials.
What We Don't Know Yet
Long-term safety and efficacy data from completed Phase 3 trials and regulatory review are not yet available. GLP-3R as a specific Elan Vital RX formulation has not undergone independent clinical trials of its own.
Areas of Research
Metabolic Health
Triple-receptor activation is being studied for its combined effects on blood sugar and energy metabolism.
Weight Management
Published trial data has examined body weight changes in study participants over defined trial periods.
Why Might Someone Discuss This With Their Provider?
Someone following emerging metabolic research may encounter GLP-3R while researching next-generation incretin and glucagon receptor therapies.
Whether a therapy is appropriate depends on individual health history, medications, goals and clinician evaluation.
Important Considerations
Retatrutide, the active investigational compound represented by GLP-3R, has not received FDA approval. GLP-3R is Elan Vital RX's own product name and is not an FDA-approved branded drug product.
Because retatrutide remains investigational, the evidence base is earlier-stage than for already-approved therapies. Side effects observed in trials have included gastrointestinal symptoms. Discuss candidacy and risks with a licensed healthcare provider.
Related Peptides
GLP-2T
A metabolic health therapy built on tirzepatide, a dual-receptor compound studied extensively for its effects on blood sugar and body weight.
MOTS-C
A mitochondria-derived peptide studied for its proposed role in cellular energy regulation and metabolic signaling.
Research & References
No references have been added for this entry yet. This library is updated on an ongoing basis.
The Peptide User Guide is provided for educational purposes and is not intended to diagnose, treat, cure, prevent, or provide individualized medical advice. Research surrounding many peptides and investigational therapies continues to evolve, and the strength of evidence varies significantly between compounds and applications. Treatment decisions should be made in consultation with a qualified healthcare professional.